Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
La ribonucleoprotein domain family member 4B (LARP4B)
- Target
- LARP4B
- Molecular classification
- RNA binding protein, La-related protein family member, Post-transcriptional regulator
01
Overview
La ribonucleoprotein domain family member 4B (LARP4B) is a cytoplasmic RNA-binding protein characterized by a conserved La motif and RNA recognition motifs (RRMs). It plays an important regulatory role in translation and mRNA metabolism, participating in posttranscriptional gene regulation. LARP4B expression is linked to prognosis in several cancers including liver cancer, where high expression indicates poor outcomes. The protein regulates key cell cycle pathways and may act via pathways involving E2F, G2M checkpoint, and mitotic spindle apparatus. LARP4B is considered a promising biomarker for cancer diagnosis and prognosis and is a potential (though not yet clinically validated) therapeutic target.
- Other names
- LARP4BKIAA0217LARP5La ribonucleoprotein 4B
02
Mechanism of action
No approved drugs directly targeting LARP4B. Inferred mechanisms would affect mRNA stability, translation, and cell cycle regulation in cancer. Mechanistic data for future RNA-binding protein antagonists/modulators could apply here.
03
Biological functions
Regulation of mRNA stability and metabolismStimulation of mRNA translationModulation of cell cycle progression via pathways (E2F targets, G2M checkpoint, mitotic spindle)Inhibition or promotion of cancer cell migration/invasion (context-dependent)Influences cell morphology (possible, based on LARP family data)
04
Disease associations
Cancer (diagnostic/prognostic biomarker in liver cancer, can modulate prognosis in glioma and other malignancies such as medulloblastoma, colorectal, pancreatic, and malignant peripheral nerve sheath tumors)Intracranial vasospasmCardiovascular syphilis (gene-disease association; clinical relevance unclear)
05
Safety considerations
Manipulation of RNA-binding proteins may affect fundamental cell cycle functions and global RNA metabolism; off-target effects and risk to normal cell viability are possible. No drug-specific safety data for LARP4B.
06
Interacting drugs
No specific drugs are documented to interact with LARP4B itself. Further research needed; refer to platforms tracking gene-drug interactions (e.g., Open Targets Platform).
07
Biomarkers
LARP4B expression level is being evaluated as a diagnostic/prognostic biomarker for liver cancer and possibly other cancers. High LARP4B is linked to poor survival in liver cancer.
Beyond the preview
Go deeper on La ribonucleoprotein domain family member 4B (LARP4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on La ribonucleoprotein domain family member 4B (LARP4B).